Celcuity’s stock surged 661% last year, to a $5 billion valuation as it moved from a clinical-stage biotech firm to a commercial-stage tumor powerhouse.

Short interest has tracked the stock's rise and currently sits at 20%, with a squeeze score hitting 100 now 87.5, and crowded score of 77.5, showing risk.

Optimists point to the potential approval of a new drug and analyst support, skeptics focus on the lack of profits, competition, and extreme recent gains.

Celcuity (CELC) is a biotechnology company focused on oncology-driven tumor therapies. The stock rose 661% last year and is now a $5B company, following its transition from clinical-stage development to commercialization.

As the stock rallied, short interest increased alongside it, causing price and short interest data to move in parallel.

This reflects a reversal-style short selling strategy, with short interest now near 20% of float, and investors added short exposure into strength and covered positions during pullbacks.

Bulls point to potential Gedatolisib approval, strong momentum, analyst support, and favorable cash and debt levels.

Bears focus on the lack of profitability, regulatory approval risk, competitive pressures, and the stock’s extreme prior gains.

The crowded score has risen alongside short interest and now stands at 77.5. As a result, any positive price move pushes the short squeeze score further above the 70-risk threshold.

The short squeeze score repeatedly hit 100 during the second half of 2025, even when the crowded score was lower. The level is currently 87.5.

Given the positive relationship between stock price and short interest, CELC is likely to become less crowded during declines and more crowded during rallies.

The losses for the shorts have been catastrophic, equal to almost the original market value of the company, and currently, 10% of the market value.

Want to know more? Access this data in real time using S3’s BLACK APP & BLACK MAP

The information herein (some of which has been obtained from third party sources without verification) is believed by S3 Partners, LLC (“S3 Partners”) to be reliable and accurate. Neither S3 Partners nor any of its affiliates makes any representation as to the accuracy or completeness of the information herein or accepts liability arising from its use. Prior to making any decisions based on the information herein, you should determine, without reliance upon S3 Partners, the economic risks, and merits, as well as the legal, tax, accounting, and investment consequences, of such decisions.